APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human iPSCs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human iPSCs Market Analysis and Forecast 2026-2032

2 January 2026194 pages

Choose your research edition.

Industry ResearchHuman iPSCs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Human iPSCs Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Human iPSCs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human iPSCs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Human iPSCs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Human iPSCs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human iPSCs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human iPSCs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human iPSCs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human iPSCs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Human iPSCs include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human iPSCs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human iPSCs, also provides the revenue of main regions and countries. Of the upcoming market potential for Human iPSCs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human iPSCs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human iPSCs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Human iPSCs revenue, projected growth trends, production technology, application and end-user industry.

Human iPSCs Segment by Company

Sumitomo Dainippon Pharma

ReproCELL

Pluricell Biotech

Ncardia

Fujifilm Holding Corporation (CDI)

Fate Therapeutics, Inc

Cell Inspire Biotechnology

Astellas Pharma Inc

Human iPSCs Segment by Type

Skin

Blood Cells

Human iPSCs Segment by Application

Regenerative Medicine

Drug Development and Discovery

Academic Research

Toxicity Screening

Others

Human iPSCs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Human iPSCs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Human iPSCs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human iPSCs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human iPSCs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Skin Major Player Table 3. Blood Cells Major Player Table 4. Global Human iPSCs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Regenerative Medicine Major Player Table 6. Drug Development and Discovery Major Player Table 7. Academic Research Major Player Table 8. Toxicity Screening Major Player Table 9. Others Major Player Table 10. Human iPSCs Industry Trends Table 11. Human iPSCs Industry Drivers Table 12. Human iPSCs Industry Opportunities and Challenges Table 13. Human iPSCs Industry Restraints Table 14. Global Human iPSCs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Human iPSCs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Human iPSCs Market Share by Region (2021-2026) Table 17. Global Human iPSCs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Human iPSCs Market Share by Region (2027-2032) Table 19. Global Human iPSCs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Human iPSCs Revenue Market Share by Players (2021-2026) Table 21. Global Human iPSCs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Human iPSCs Key Players Headquarters & Area Served Table 23. Global Human iPSCs Players, Product Type & Application Table 24. Global Human iPSCs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Human iPSCs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Human iPSCs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human iPSCs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Human iPSCs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Human iPSCs Revenue Market Share by Type (2021-2026) Table 31. Global Human iPSCs Revenue Market Share by Type (2027-2032) Table 32. Global Human iPSCs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Human iPSCs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Human iPSCs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Human iPSCs Revenue Market Share by Application (2021-2026) Table 36. Global Human iPSCs Revenue Market Share by Application (2027-2032) Table 37. Sumitomo Dainippon Pharma Company Information Table 38. Sumitomo Dainippon Pharma Business Overview Table 39. Sumitomo Dainippon Pharma Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Sumitomo Dainippon Pharma Human iPSCs Product Portfolio Table 41. Sumitomo Dainippon Pharma Recent Development Table 42. ReproCELL Company Information Table 43. ReproCELL Business Overview Table 44. ReproCELL Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. ReproCELL Human iPSCs Product Portfolio Table 46. ReproCELL Recent Development Table 47. Pluricell Biotech Company Information Table 48. Pluricell Biotech Business Overview Table 49. Pluricell Biotech Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Pluricell Biotech Human iPSCs Product Portfolio Table 51. Pluricell Biotech Recent Development Table 52. Ncardia Company Information Table 53. Ncardia Business Overview Table 54. Ncardia Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Ncardia Human iPSCs Product Portfolio Table 56. Ncardia Recent Development Table 57. Fujifilm Holding Corporation (CDI) Company Information Table 58. Fujifilm Holding Corporation (CDI) Business Overview Table 59. Fujifilm Holding Corporation (CDI) Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio Table 61. Fujifilm Holding Corporation (CDI) Recent Development Table 62. Fate Therapeutics, Inc Company Information Table 63. Fate Therapeutics, Inc Business Overview Table 64. Fate Therapeutics, Inc Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Fate Therapeutics, Inc Human iPSCs Product Portfolio Table 66. Fate Therapeutics, Inc Recent Development Table 67. Cell Inspire Biotechnology Company Information Table 68. Cell Inspire Biotechnology Business Overview Table 69. Cell Inspire Biotechnology Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Cell Inspire Biotechnology Human iPSCs Product Portfolio Table 71. Cell Inspire Biotechnology Recent Development Table 72. Astellas Pharma Inc Company Information Table 73. Astellas Pharma Inc Business Overview Table 74. Astellas Pharma Inc Human iPSCs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Astellas Pharma Inc Human iPSCs Product Portfolio Table 76. Astellas Pharma Inc Recent Development Table 77. North America Human iPSCs Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Human iPSCs Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Human iPSCs Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Human iPSCs Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Human iPSCs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Human iPSCs Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Human iPSCs Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Human iPSCs Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Human iPSCs Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Human iPSCs Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Human iPSCs Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Human iPSCs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Human iPSCs Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Human iPSCs Revenue by Country (US$ Million) & (2027-2032) Table 91. China Human iPSCs Revenue by Type (2021-2026) & (US$ Million) Table 92. China Human iPSCs Revenue by Type (2027-2032) & (US$ Million) Table 93. China Human iPSCs Revenue by Application (2021-2026) & (US$ Million) Table 94. China Human iPSCs Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Human iPSCs Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Human iPSCs Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Human iPSCs Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Human iPSCs Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Human iPSCs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Human iPSCs Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Human iPSCs Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Human iPSCs Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Human iPSCs Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Human iPSCs Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Human iPSCs Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Human iPSCs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Human iPSCs Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Human iPSCs Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Human iPSCs Image Figure 2. Global Human iPSCs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human iPSCs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Skin Image Figure 5. Blood Cells Image Figure 6. Global Human iPSCs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Human iPSCs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Regenerative Medicine Image Figure 9. Drug Development and Discovery Image Figure 10. Academic Research Image Figure 11. Toxicity Screening Image Figure 12. Others Image Figure 13. Global Human iPSCs Market Size (US$ Million) & (2021-2032) Figure 14. Global Human iPSCs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Human iPSCs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Human iPSCs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Human iPSCs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Human iPSCs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Human iPSCs Revenue Market Share by Type (2021-2032) Figure 21. Global Human iPSCs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Human iPSCs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Human iPSCs Revenue Market Share by Application (2021-2032) Figure 24. North America Human iPSCs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Human iPSCs Revenue Share by Type (2021-2032) Figure 26. North America Human iPSCs Revenue Share by Application (2021-2032) Figure 27. North America Human iPSCs Revenue Share by Country (2021-2032) Figure 28. United States Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Human iPSCs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Human iPSCs Revenue Share by Type (2021-2032) Figure 33. Europe Human iPSCs Revenue Share by Application (2021-2032) Figure 34. Europe Human iPSCs Revenue Share by Country (2021-2032) Figure 35. Germany Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Human iPSCs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Human iPSCs Revenue Share by Type (2021-2032) Figure 45. China Human iPSCs Revenue Share by Application (2021-2032) Figure 46. Asia Human iPSCs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Human iPSCs Revenue Share by Type (2021-2032) Figure 48. Asia Human iPSCs Revenue Share by Application (2021-2032) Figure 49. Asia Human iPSCs Revenue Share by Region (2021-2032) Figure 50. Japan Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Human iPSCs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Human iPSCs Revenue Share by Type (2021-2032) Figure 58. SAMEA Human iPSCs Revenue Share by Application (2021-2032) Figure 59. SAMEA Human iPSCs Revenue Share by Country (2021-2032) Figure 60. Brazil Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Human iPSCs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Skin
  • Blood Cells
Applications
  • Regenerative Medicine
  • Drug Development and Discovery
  • Academic Research
  • Toxicity Screening
  • Others
Companies covered
  • Sumitomo Dainippon Pharma
  • ReproCELL
  • Pluricell Biotech
  • Ncardia
  • Fujifilm Holding Corporation (CDI)
  • Fate Therapeutics, Inc
  • Cell Inspire Biotechnology
  • Astellas Pharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human iPSCs Market by Type
  3. 1.2.1 Global Human iPSCs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Skin
  5. 1.2.3 Blood Cells
  6. 1.3 Human iPSCs Market by Application
  7. 1.3.1 Global Human iPSCs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Regenerative Medicine
  9. 1.3.3 Drug Development and Discovery
  10. 1.3.4 Academic Research
  11. 1.3.5 Toxicity Screening
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Human iPSCs Market Dynamics
  1. 2.1 Human iPSCs Industry Trends
  2. 2.2 Human iPSCs Industry Drivers
  3. 2.3 Human iPSCs Industry Opportunities and Challenges
  4. 2.4 Human iPSCs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Human iPSCs Market Perspective (2021-2032)
  2. 3.2 Global Human iPSCs Growth Trends by Region
  3. 3.2.1 Global Human iPSCs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human iPSCs Market Size by Region (2021-2026)
  5. 3.2.3 Global Human iPSCs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Human iPSCs Revenue by Players
  2. 4.1.1 Global Human iPSCs Revenue by Players (2021-2026)
  3. 4.1.2 Global Human iPSCs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Human iPSCs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human iPSCs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Human iPSCs Key Players Headquarters & Area Served
  7. 4.4 Global Human iPSCs Players, Product Type & Application
  8. 4.5 Global Human iPSCs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Human iPSCs Market CR5 and HHI
  11. 4.6.3 2025 Human iPSCs Tier 1, Tier 2, and Tier 3
5 Human iPSCs Market Size by Type
  1. 5.1 Global Human iPSCs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Human iPSCs Revenue by Type (2021-2032)
  3. 5.3 Global Human iPSCs Revenue Market Share by Type (2021-2032)
6 Human iPSCs Market Size by Application
  1. 6.1 Global Human iPSCs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Human iPSCs Revenue by Application (2021-2032)
  3. 6.3 Global Human iPSCs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sumitomo Dainippon Pharma
  2. 7.1.1 Sumitomo Dainippon Pharma Company Information
  3. 7.1.2 Sumitomo Dainippon Pharma Business Overview
  4. 7.1.3 Sumitomo Dainippon Pharma Human iPSCs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
  6. 7.1.5 Sumitomo Dainippon Pharma Recent Developments
  7. 7.2 ReproCELL
  8. 7.2.1 ReproCELL Company Information
  9. 7.2.2 ReproCELL Business Overview
  10. 7.2.3 ReproCELL Human iPSCs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ReproCELL Human iPSCs Product Portfolio
  12. 7.2.5 ReproCELL Recent Developments
  13. 7.3 Pluricell Biotech
  14. 7.3.1 Pluricell Biotech Company Information
  15. 7.3.2 Pluricell Biotech Business Overview
  16. 7.3.3 Pluricell Biotech Human iPSCs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pluricell Biotech Human iPSCs Product Portfolio
  18. 7.3.5 Pluricell Biotech Recent Developments
  19. 7.4 Ncardia
  20. 7.4.1 Ncardia Company Information
  21. 7.4.2 Ncardia Business Overview
  22. 7.4.3 Ncardia Human iPSCs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Ncardia Human iPSCs Product Portfolio
  24. 7.4.5 Ncardia Recent Developments
  25. 7.5 Fujifilm Holding Corporation (CDI)
  26. 7.5.1 Fujifilm Holding Corporation (CDI) Company Information
  27. 7.5.2 Fujifilm Holding Corporation (CDI) Business Overview
  28. 7.5.3 Fujifilm Holding Corporation (CDI) Human iPSCs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
  30. 7.5.5 Fujifilm Holding Corporation (CDI) Recent Developments
  31. 7.6 Fate Therapeutics, Inc
  32. 7.6.1 Fate Therapeutics, Inc Company Information
  33. 7.6.2 Fate Therapeutics, Inc Business Overview
  34. 7.6.3 Fate Therapeutics, Inc Human iPSCs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Fate Therapeutics, Inc Human iPSCs Product Portfolio
  36. 7.6.5 Fate Therapeutics, Inc Recent Developments
  37. 7.7 Cell Inspire Biotechnology
  38. 7.7.1 Cell Inspire Biotechnology Company Information
  39. 7.7.2 Cell Inspire Biotechnology Business Overview
  40. 7.7.3 Cell Inspire Biotechnology Human iPSCs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Cell Inspire Biotechnology Human iPSCs Product Portfolio
  42. 7.7.5 Cell Inspire Biotechnology Recent Developments
  43. 7.8 Astellas Pharma Inc
  44. 7.8.1 Astellas Pharma Inc Company Information
  45. 7.8.2 Astellas Pharma Inc Business Overview
  46. 7.8.3 Astellas Pharma Inc Human iPSCs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Astellas Pharma Inc Human iPSCs Product Portfolio
  48. 7.8.5 Astellas Pharma Inc Recent Developments
8 North America
  1. 8.1 North America Human iPSCs Revenue (2021-2032)
  2. 8.2 North America Human iPSCs Revenue by Type (2021-2032)
  3. 8.2.1 North America Human iPSCs Revenue by Type (2021-2026)
  4. 8.2.2 North America Human iPSCs Revenue by Type (2027-2032)
  5. 8.3 North America Human iPSCs Revenue Share by Type (2021-2032)
  6. 8.4 North America Human iPSCs Revenue by Application (2021-2032)
  7. 8.4.1 North America Human iPSCs Revenue by Application (2021-2026)
  8. 8.4.2 North America Human iPSCs Revenue by Application (2027-2032)
  9. 8.5 North America Human iPSCs Revenue Share by Application (2021-2032)
  10. 8.6 North America Human iPSCs Revenue by Country
  11. 8.6.1 North America Human iPSCs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Human iPSCs Revenue by Country (2021-2026)
  13. 8.6.3 North America Human iPSCs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Human iPSCs Revenue (2021-2032)
  2. 9.2 Europe Human iPSCs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Human iPSCs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Human iPSCs Revenue by Type (2027-2032)
  5. 9.3 Europe Human iPSCs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Human iPSCs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Human iPSCs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Human iPSCs Revenue by Application (2027-2032)
  9. 9.5 Europe Human iPSCs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Human iPSCs Revenue by Country
  11. 9.6.1 Europe Human iPSCs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Human iPSCs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Human iPSCs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Human iPSCs Revenue (2021-2032)
  2. 10.2 China Human iPSCs Revenue by Type (2021-2032)
  3. 10.2.1 China Human iPSCs Revenue by Type (2021-2026)
  4. 10.2.2 China Human iPSCs Revenue by Type (2027-2032)
  5. 10.3 China Human iPSCs Revenue Share by Type (2021-2032)
  6. 10.4 China Human iPSCs Revenue by Application (2021-2032)
  7. 10.4.1 China Human iPSCs Revenue by Application (2021-2026)
  8. 10.4.2 China Human iPSCs Revenue by Application (2027-2032)
  9. 10.5 China Human iPSCs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human iPSCs Revenue (2021-2032)
  2. 11.2 Asia Human iPSCs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Human iPSCs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Human iPSCs Revenue by Type (2027-2032)
  5. 11.3 Asia Human iPSCs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Human iPSCs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Human iPSCs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Human iPSCs Revenue by Application (2027-2032)
  9. 11.5 Asia Human iPSCs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Human iPSCs Revenue by Country
  11. 11.6.1 Asia Human iPSCs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Human iPSCs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Human iPSCs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human iPSCs Revenue (2021-2032)
  2. 12.2 SAMEA Human iPSCs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Human iPSCs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Human iPSCs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Human iPSCs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Human iPSCs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Human iPSCs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Human iPSCs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Human iPSCs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Human iPSCs Revenue by Country
  11. 12.6.1 SAMEA Human iPSCs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Human iPSCs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Human iPSCs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst